Inmune Bio, Inc. Income Statement
INMB|7 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Inmune Bio, Inc. reported $14,000 in revenue and $42M in net loss for FY2025. Revenue has grown at a 5.1% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $14.0K | $155.0K | $374.0K | $181.0K | $11.0K | $10.9K | $0 |
| SG&A Expense | $9.5M | $9.6M | $9.3M | $8.8M | $6.3M | $6.0M | $546.1K |
| R&D Expense | $33.2M | $20.3M | $17.1M | $20.5M | $5.9M | $3.3M | $435.4K |
| Operating Income | -$42.6M | -$29.7M | -$26.0M | -$29.2M | -$12.2M | -$7.8M | -$981.5K |
| Interest Expense | $789.0K | $2.3M | $2.0M | $985.0K | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 |
| Net Income | -$42.1M | -$30.0M | -$27.3M | -$30.3M | -$12.1M | -$7.7M | -$831.5K |
| EPS (Basic) | -$2.11 | -$1.67 | -$1.52 | -$1.88 | - | - | - |
| EPS (Diluted) | -$2.11 | -$1.67 | -$1.52 | -$1.88 | -$1.01 | -$0.75 | -$0.13 |
| Shares Outstanding | 22.3M | 18.0M | 17.9M | 17.8M | 13.5M | 10.8M | 8.3M |
| Operating Margin | -304535.7% | -19187.7% | -6938.8% | -16106.6% | -111163.6% | -71051.7% | - |
| Profit Margin | -300585.7% | -19360.0% | -7299.2% | -16762.4% | -109990.9% | -70340.0% | - |